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mode of action and the binding site on
the β2 subunit of GABAA receptors?
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ABSTRACT
NA-glycine is an endogenous lipid molecule with analgesic properties, which is struc-
turally similar to the endocannabinoids 2-AG and anandamide but does not interact
with cannabinoid receptors. NA-glycine has been suggested to act at the G-protein
coupled receptors GPR18 and GPR92. Recently, we have described that NA-glycine
can also modulate recombinant α1β2γ2 GABAA receptors. Here we characterize in
more detail this modulation and investigate the relationship of its binding site with
that of the endocannabinoid 2-AG.
Subjects Biochemistry, Neuroscience, Pharmacology
Keywords GABAA receptors, Endocannabinoids, GABA, 2-AG, NA-glycine
INTRODUCTION
GABA is the major inhibitory neurotransmitter in mammalian brain. Its fast effects are
mediated by synaptic and extrasynaptic GABAA receptors. These receptors are composed
of five subunits that surround a central chloride ion channel (Macdonald & Olsen, 1994;
Sieghart, 1995; Sieghart & Sperk, 2002; Sigel & Steinmann, 2012). The major receptor
isoform consists of α1, β2, and γ2 subunits (Olsen & Sieghart, 2008). Different approaches
led to the widely accepted 2α:2β:1γ subunit stoichiometry (Chang et al., 1996; Tretter et al.,
1997; Farrar et al., 1999; Baumann, Baur & Sigel, 2001; Baumann, Baur & Sigel, 2002; Baur,
Minier & Sigel, 2006) with a subunit arrangement γβαβα anti-clockwise as seen from the
synaptic cleft (Baumann, Baur & Sigel, 2001; Baumann, Baur & Sigel, 2002; Baur, Minier
& Sigel, 2006). The pharmacological properties are dependent on subunit composition
(Sigel et al., 1990) and arrangement (Minier & Sigel, 2004).
Neurosteroids (Belelli & Lambert, 2005) and the endocannabinoid 2-AG (Sigel et al.,
2011) have been documented as endogenous ligands of GABAA receptors. A binding
site for 2-AG has been shown to be present specifically on each of the two β2 subunits
present in a pentameric receptor. Moreover it has been proposed that 2-AG dips into
the membrane and binds to the fourth trans-membrane sequence (M4) of β2 subunits
(Baur et al., 2013).
NA-glycine has been shown to be present in amounts of about 50 pmol/g dry weight
in rat brain tissue and about 140 pmol/g dry weight in spinal cord (Huang et al.,
2001). This can be compared to the levels of 2-AG that have been reported to be 4 and
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50 nmol/g wet weight in brain (Sigel et al., 2011) and spinal cord (Guasti et al., 2009),
respectively. Thus, NA-glycine is about 1000-fold less abundant than 2-AG. NA-glycine
has no functional affinity for CB1 receptors (Sheskin et al., 1997), but may activate the G
protein coupled receptors GPR18 (Kohno et al., 2006) and GPR92 (Oh et al., 2008) and
target Na+/Ca2+-exchanger NCX (Bondarenko et al., 2013) and T-type Ca2+-channels
(Barbara et al., 2009). Interestingly, NA-glycine exerts analgesic properties in different
rodent models of pain (Huang et al., 2001; Succar, Mitchell & Vaughan, 2007). Recently, it
has been reported that NA-glycine can also interact with glycine receptors, potentiating α1
and interestingly inhibiting α2 and α3-containing glycine receptors (Yevenes & Zeilhofer,
2011). It should be noted that NA-glycine functionally interacts with glycine receptors
with an apparent affinity>10 µM. This should be compared to the functional affinities to
GABAA receptors, NCX and T-type Ca2+-channels that are estimated<10 µM.
We have previously demonstrated that NA-glycine allosterically potentiates GABAA
receptors (Baur et al., 2013), but it remained unclear whether this occurred via the same
binding site as 2-AG. The aim of the present study was therefore to establish whether
NA-glycine acts at the identical site on GABAA receptors as 2-AG. In most studied
aspects Na-glycine acts similar to 2-AG, indicating a common binding site. However,
some point mutations that abrogate modulation by 2-AG leave the initial modulation by
NA-glycine nearly unaffected and only over time the modulation is gradually decreased
to zero. Differential solubilization effects of 2-AG and NA-glycine may account for this
phenomena. Thus, at least during initial phases of interaction with GABAA receptors the
mode of binding is different for the two compounds.
METHODS
Material
2-AG and NA-glycine were obtained from Cayman Chemical (Chemie Brunschwig, Basel,
Switzerland). All other chemicals, unless mentioned otherwise below, were from Sigma
(Buchs, Switzerland).
Expression of GABAA receptors in Xenopus oocytes
Capped cRNAs were synthesized (Ambion, Austin, TX, USA) from the linearized plasmids
with a cytomegalovirus promotor (pCMV vectors) containing the different subunits,
respectively. A poly-A tail of about 400 residues was added to each transcript using yeast
poly-A polymerase (United States Biologicals, Cleveland, OH, USA). The concentration
of the cRNA was quantified on a formaldehyde gel using Radiant Red stain (Bio-Rad
Laboratories, Reinach, Switzerland) for visualization of the RNA. Known concentrations
of RNA ladder (Invitrogen, Life Technologies, Zug, Switzerland) were loaded as standard
on the same gel. cRNAs were precipitated in ethanol/isoamylalcohol 19 : 1, the dried
pellet dissolved in water and stored at−80◦C. cRNA mixtures were prepared from these
stock solutions and stored at −80◦C. Xenopus laevis oocytes were prepared, injected
and defolliculated as described previously (Sigel, 1987; Sigel & Minier, 2005; Animal
Permit No. BE98/12, Kantonaler Verterina¨rdienst, Kanton Bern). They were injected
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with 50 nL of the cRNA solution containing rat wild type α1 and wild type or mutated
β2 and wild type γ2 subunits at a concentration of 10 nM:10 nM 50 nM (Boileau et
al., 2002) and then incubated in modified Barth’s solution at +18◦C for at least 24 h
before the measurements. Where indicated concatenated subunits α1-β2-α1/γ2-β2 or
α1-β2-α1/γ2-β1 or α1-β1-α1/γ2-β2 or α1-β1-α1/γ2-β1 were used at a concentration of
25 nM:25 nM, each.
Functional characterization of the GABAA receptors
Currents were measured using a modified two-electrode voltage clamp amplifier Oocyte
clamp OC-725 (Warner Instruments, Camden, CT, USA) in combination with a
XY-recorder (90% response time 0.1 s) or digitized at 100 Hz using a PowerLab 2/20 (AD
Instruments) using the computer programs Chart (ADInstruments GmbH, Spechbach,
Germany). Tests with a model oocyte were performed to ensure linearity in the larger
current range. The response was linear up to 15 µA.
Electrophysiological experiments were performed using the two-electrode voltage
clamp method at a holding potential of −80 mV. The perfusion medium contained
90 mM NaCl, 1 mM KCl, 1 mM MgCl2, 1 mM CaCl2, 5 mM Na-HEPES (pH 7.4) and
0.5% DMSO and was applied by gravity flow 6 ml/min. The perfusion medium was applied
through a glass capillary with an inner diameter of 1.35 mm, the mouth of which was
placed about 0.4 mm from the surface of the oocyte. Allosteric modulation via the 2-AG
site was measured at a GABA concentration eliciting about 1% of the maximal GABA
current amplitude (EC1). In each experiment, 1 mM GABA was applied to determine
the maximal current amplitude. Subsequently increasing concentrations of GABA were
applied until 0.5%–1% of the maximal current amplitude was elicited (0.3–3 µM). For
modulation experiments, GABA was applied for 20 s alone or in combination with 2-AG or
NA-glycine. 2-AG or NA-glycine were pre-applied for 30 s. Modulation of GABA currents
was expressed as (I(modulator+GABA)/IGABA–1) ∗ 100%. Inhibition by DEA was determined
at the end of a 1 min co-application with either NA-glycine or 2-AG following a 30 s
pre-application of both compounds. The perfusion system was cleaned between drug
applications by washing with dimethylsulfoxide to avoid contamination.
Determination of critical micelle concentrations (CMC)
Assays were performed as reported previously (Raduner et al., 2007). In brief, compounds
(from 2 mM stock solutions) were incubated at increasing concentrations with 0.1 nM
fluorescein (free acid, 99%, Fluka, Switzerland) for 90 min at 30◦C in Nanopure distilled
water. Experiments were carried out on 96-well microtiter plates (excitation at 485 nm,
emission at 535 nm) on a TECAN Farcyte reader. Experiments were performed in
triplicates in three independent experiments and data are mean values± S.D.
RESULTS
Both NA-glycine and 2-AG allosterically potentiate recombinant α1β2γ2 GABAA receptors
expressed in Xenopus oocytes. Both compounds share the arachidonoyl tail structure
but differ in their hydrophilic head groups (Fig. 1). Please note that at physiological pH,
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Figure 1 Chemical structure of NA-glycine and 2-AG.
NA-glycine is negatively charged. Here we wanted to compare the GABAA receptor binding
site for NA-glycine with the well-characterized binding site for 2-AG.
Figure 2A shows current traces of a cumulative concentration–response curve of the
allosteric potentiation of α1β2γ2 GABAA receptors at a GABA concentration of 1 µM. At
the highest concentration used the current trace displayed the typical signs of an open
channel block, rapid apparent desensitization and an off current. This phenomenon made
a precise curve fit impossible as maximal potentiation could not be determined precisely.
The averaged concentration–response curve (Fig. 2B) was fitted with the assumption of
different maximal potentiation. From these fits it was estimated that the EC50 was between
1 and 10 µM (not shown). Direct activation by 3 µM NA-glycine elicited no significant
current (<2 nA) in oocytes where 100 µM GABA elicited a current>7 µA.
Allosteric potentiation by 3 µM NA-glycine was determined at different concentrations
of the endogenous agonist GABA. Figure 3 shows that the degree of potentiation was
rapidly decreasing with increasing concentrations of GABA. The comparable properties
of 2-AG are also shown in Fig. 3. We tried to rationalize these findings using a model that
has previously been proposed on the basis of other observations (Baumann, Baur & Sigel,
2003; Fig. 4A). This model assumes binding of GABA to two sites differing in their binding
affinity and transition to the open state with low propensity of singly ligated states and high
propensity of the doubly ligated state. Figure 4B shows computed current amplitudes in
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Figure 2 Concentration-dependent potentiation of currents mediated by recombinant α1β2γ2
GABAA receptors. (A) Receptors were expressed in Xenopus oocytes and currents were measured by
using electrophysiological techniques at a GABA concentration eliciting 0.5–1.0% of the maximal current
amplitude (EC0.5–1.0). GABA was applied twice (single bars) and subsequently in combination with
increasing concentrations of NA-glycine. The numbers above the double bars indicate the concentration
of NA-glycine in µM. NA-glycine was pre-applied for 30 s. Original current traces are shown. (B) shows
the averaged concentration-dependent potentiation of currents elicited by GABA by NA-glycine. Four
experiments as shown under (A) were averaged. Data are shown as mean± SD (n= 4). Such an averaged
curve has been shown before based on 3 experiments and missing the point at 10 µM NA-glycine
(Baur et al., 2013).
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Figure 3 Influence of the GABA concentration. Current potentiation by 3 µM NA-glycine (closed
circles) or 2-AG (closed squares) was determined at different concentrations of GABA. Potentiation
decreased with increasing concentrations of GABA. The GABA concentration response curve was fitted
with a mean EC50 of 35 µM and a mean Hill coefficient of 1.5 (not shown).
dependence of the GABA concentration. In addition, a predicted curve is shown where it is
assumed that NA-glycine promotes transition of the singly ligated receptor from the closed
to the open state. Figure 4C shows a computed GABA concentration-dependence of the
current potentiation expected in this case. The model predicts that sizeable potentiation is
limited to very low concentrations of GABA.
We have previously shown that the CB1 receptor ligand DEA antagonizes potentiation
by 2-AG (Baur et al., 2013). Therefore, we compared the ability of DEA to antagonize
potentiation by NA-glycine and 2-AG. Based on the structural similarity of the three
compounds we assumed a competitive behaviour. Figure 5 compares the cumulative
concentration inhibition curves for 3 µM NA-glycine and for 3 µM 2-AG. Potentiation
by NA-glycine was inhibited half-maximally at 72± 36 µM (n= 4) DEA and potentiation
by 2-AG at 1.4± 0.6 µM (n = 6). If the two ligands displayed a similar apparent affinity
for potentiation at the same site where DEA acts, providing equal water solubility and
lipid solubilization, a similar inhibitory potency of DEA would have been expected. In
order to investigate if DEA and NA-glycine act competitively, we repeated a concentration
inhibition curves at 6-times lower concentration (0.5 µM) of NA-glycine. Half-maximal
inhibition was observed at 96± 41 µM (n = 4) DEA (Fig. 5). This could be interpreted
as non-competitive interaction of DEA with NA-glycine. Similarly, we performed
concentration inhibition curves at 1 and 15 µM 2-AG. The higher concentration of 2-AG
elicits direct current that amount to less than 0.1% of the maximal current amplitude
elicited by GABA in the same oocytes. As expected for a competitive interaction between
2-AG and DEA, half-maximal inhibition was shifted to the left upon decrease of the
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Figure 4 Mode of action of NA-glycine. Simplified model (A) The model assumes two agonist binding
sites 1 and 2 with different affinities. 2-AG affects the closed/open transition of the two singly ligated
states. The receptor R can first bind GABA (A) either to the site 1 (AR) or the site 2 (RA). The receptor
occupied by two agonist molecules ARA can isomerize to the open state ARA*, the receptors occupied
by a single agonist molecule can isomerize to the open states AR* and RA*. Binding is described with K
as dissociation constants and gating with L as closed state/open state equilibrium. (C) Theoretical GABA
concentration response curves in the absence and presence of NA-glycine. The following parameters were
assumed: 0.24 for L, 10 and 2.2 for L1 in the absence and presence of NA-glycine, respectively, 11 and 2.4
for L2 in the absence (line) and presence (dashed line) of NA-glycine, respectively, 30 µM for K1, 90 µM
for K2. (C) Dependence of the potentiation by NA-glycine on the concentration of GABA obtained by
the ratio of the computed current in the presence of NA-glycine divided by the current in its absence.
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Figure 5 Concentration inhibition curve of DEA. Increasing concentrations of DEA were co-applied
with 1 µM 2-AG (open circles), 3 µM 2-AG (open squares), 15 µM 2-AG (open diamonds), 0.5 µM
NA-glycine (filled circles), or 3 µM NA-glycine (filled squares). Data are shown as mean± SEM (n= 4).
2-AG concentration from 3 µM to 1 µM, but the inhibition curve became much flatter,
indicating the DEA becomes partially inactive at higher concentrations. Half-maximal
inhibition for 15 µM was not reached at concentrations up to 100 µM (n = 4) DEA
(Fig. 5). In case of a non-competitive interaction of DEA with 2-AG an IC50 of about
1.4 µM and in case of a competitive interaction an IC50 of about 7 µM would be expected
in the latter case. The observed results cannot be explained by classical receptor theory
and we therefore speculate that 2-AG and NA-glycine exhibit a different water solubility
and lipid solubilisation in the experimental setup. In the discussion we mention possible
explanations.
NA-glycine shows higher efficacy than 2-AG for potentiation of currents elicited by
GABA. 2-AG is metabolically stable in Xenopus oocytes as no degradation by serine
hydrolases was found (not shown). In case NA-glycine competes for the same binding site
as 2-AG and both molecules have a similar apparent affinity to this binding site, it would be
anticipated that the degree of potentiation by both agents at the same concentration would
result in an intermediate potentiation as compared to the individual agents. The apparent
affinity of 2-AG has been determined as 2 µM, while the apparent affinity of NA-glycine is
estimated 1–10 µM here. As shown in Fig. 6A, combined application results surprisingly in
nearly the same extent of potentiation as application of NA-glycine alone.
Again, this may be caused by a differential water solubility and membrane solubil-
isation behaviour of NA-glycine and 2-AG. We therefore measured the critical micelle
concentrations of both molecules. The apparent CMC was>100 µM for NA-glycine and
4.2± 0.5 µM for 2-AG, pointing to significant self-assembly and detergent behaviour of
2-AG.
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Figure 6 Effect of subunit combination and co-application with 2-AG. (A) Current potentiation by the
combined application of 3 µM NA-glycine and 3 µM 2-AG is compared with the individual application
of the two substances. (B) Current potentiation by 3 µM NA-glycine in α1β2γ2 receptors and α1β1γ2
receptors. Potentiation is strongly dependent on the presence of the β2 subunit.
As 2-AG fails to potentiate in GABAA receptors where the β2 subunit is replaced by
β1, we tested potentiation by NA-glycine in α1β1γ2 receptors (Fig. 6B). Similarly to
2-AG, potentiation by NA-glycine depends on the presence of β2 subunits. We studied
potentiation by NA-glycine in concatenated receptors containing either two β2 subunits,
two β1 subunits or one each β1 and β2 in different positions in the receptor pentamer
(Fig. 7). Receptors containing two β2 subunits exhibited strong potentiation while
receptors containing two β1 subunits showed very weak potentiation. Intermediate
potentiation was observed in receptors containing one each, β1 and β2. This strongly
indicates that the NA-glycine binding site is located on the β2 subunit as previously shown
with 2-AG (Sigel et al., 2011).
A number of point mutations have been described to interfere with the potentiation by
2-AG. We tested the effect of the point mutations β2W428C, β2S429C, β2F432C, β2F439L
and β2V443C. Original current traces are shown for the mutant receptor α1β2S429Cγ2.
These traces are compared with traces from wild type receptors (Fig. 8A). While wild type
receptors show a time-independent potentiation by NA-glycine, mutant receptors showed
initially a potentiation that rapidly decayed over time. As these mutant receptors show a
similar dependence on GABA as wild type receptors, and the experiment were carried out
at very low GABA concentrations this current transient is not due to desensitization. In the
case of 2-AG the effect of these mutations is a reduction of the potentiation independent
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Figure 7 Concentration-dependent potentiation of currents mediated by concatenated GABAA recep-
tors. Concatenated α1-β1-α1/γ2-β1, α1-β1-α1/γ2-β2, α1-β2-α1/γ2-β1 or α1-β2-α1/γ2-β2 receptors
were expressed in Xenopus oocytes and currents were measured at a GABA concentration eliciting
0.5–1.0% of the maximal current amplitude (EC0.5–1.0). Current potentiation by increasing concen-
trations of NA-glycine was determined. Four such experiments were averaged. Data are shown as mean
± SD (n= 4).
of the time of exposure to 2-AG. This behaviour is observed with NA-glycine for the
potentiation of α1β2F432Cγ2 receptors, but not the other mutant receptors studied.
The mutation studies indicate a site of action in the inner leaflet of M4 of the β2 subunit.
In this case NA-glycine has to traverse the lipid bilayer either by diffusion or mediated by
a transport system and this may require some time. In order to test the time-dependence
of action of NA-glycine we exposed an oocyte to GABA followed by GABA and NA-glycine
(Fig. 9). Indeed, onset of modulation was slow and did not reach a steady level within
1 min. Upon switch of the medium to GABA only, a slow decay of the potentiation was
observed.
DISCUSSION
NA-glycine allosterically potentiates GABAA receptors like the major endocannabinoid
2-AG. We aimed at localizing the site of interaction of Na-glycine with recombinant
α1β2γ2 GABAA receptors relative to the site for 2-AG. An interpretation of our results
is hampered by the fact that the apparent affinity for the potentiation by NA-glycine could
not be determined accurately. However, we can estimate this value to be in the range of
1–10 µM, which compares well with the value of 2 µM for 2-AG (Sigel et al., 2011). The
fact that we find significant potentiation of GABAA receptors by>0.1 µM NA-glycine may
reflect the better water solubility of NA-glycine over 2-AG at low concentrations and even
indicate biological relevance as the average in vivo concentration in the central nervous
system may be estimated from the dry tissue content as about 15–50 nM and NA-glycine is
unlikely to be randomly distributed.
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Figure 8 Effect of point mutations that reduced potentiation by 2-AG on the potentiation of NA-
glycine. (A) Potentiation by 3 µM NA-glycine is compared between wild type receptors and receptors
containing the point mutation S429C in the β2 subunit. This mutation results at the beginning of the drug
application in an about 50% reduction of potentiation and after 1 min drug application potentiation is
abolished. (B) Wild type receptors are compared with mutant receptors. Current potentiation is indicated
at the beginning of the drug application (filled bars) and after 1 min drug exposure (open bars).
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Figure 9 Time course of the potentiation by NA-glycine. An oocyte expressing α1β2γ2 receptors was
sequentially exposed to medium alone, to 1 µM GABA, to the same concentration of GABA in combina-
tion with 5 µM NA-glycine, to 1 µM GABA alone and the to medium. This experiment was repeated two
more times with similar results.
The following observations argue for a similar mode of action of NA-glycine and 2-AG.
First, both substances only act exclusively at low GABA concentration (Fig. 3), putatively
by enhancing the opening of singly ligated receptor channels (Fig. 4). A leftward shift of
the concentration response curve for GABA as observed in the case of benzodiazepines
does not abrogate potentiation below EC50 (Sigel & Steinmann, 2012). To our knowledge,
this is a new mode of action of a ligand. Second, investigation of receptors with different β
subunits (Fig. 5) and experiments with concatenated receptors containing either no, one,
or two β2 subunits (Fig. 6) strongly indicate that both ligand binding sites are located on
the β2 subunit. A common binding site in the inner leaflet of the fourth trans-membrane
region (M4) of this subunit is suggested by the fact that modulation by both agents is either
reduced or abolished in five identical mutant receptors, at least in the late phase of action of
NA-glycine (Fig. 8B). The onset of action for both substances was found to be slow (Fig. 9;
Baur et al., 2013). On the basis of these observations, it is tempting to assume a common
binding site for the two ligands.
The following observation cannot be explained by classical receptor theory in case
NA-glycine and 2-AG use an identical binding site, i.e., display a similar apparent
affinity and interact with each other in a competitive way. Combined application of two
compounds with similar affinities at identical concentrations is then expected to result in
an intermediate potentiation as compared to that by individual compounds. Instead, the
observed potentiation is similar to the one by NA-glycine alone. A second observation is
difficult to reconcile with a common binding site for NA-glycine, 2-AG and the inhibitor of
the potentiation of 2-AG, DEA. Namely, DEA prevents potentiation by NA-glycine only at
50-fold higher concentrations as that caused by 2-AG. As mentioned in the result section,
the interaction between DEA and 2-AG cannot be explained by classical receptor theory.
Since NA-glycine exerts a significant higher CMC than 2-AG, differential solubilisation of
NA-glycine and 2-AG with Xenopus oocytes may account for some of the effects observed
in this study. The way these lipids are organized in an aqueous environment will affect
entry of the molecules into the bilayer, binding equilibrium, and the way the receptor is
occupied. If this holds true the observations with co-application of NA-glycine and 2-AG
as well as the inhibition of NA-glycine and DEA have to be seen in a new light. In spite of
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our observations the three agents could still all bind to largely overlapping sites within an
extended surface able to bind flexible hydrophobic structures.
The mutant receptors α1β2W428Cγ2, α1β2S429Cγ2, α1β2F439Lγ2 and α1β2V443Cγ2
all largely abrogate modulation by NA-glycine after 1 min of combined application of
GABA with NA-glycine. This abrogation is not present at the beginning of the combined
application, but sets in rather slowly. We have no explanation for this observation.
Solubility considerations do not help to explain this phenomenon.
Overall, most arguments point to a similar action and possibly overlapping binding site
for NA-glycine and 2-AG. No matter what the exact mode of interaction of NA-glycine
with the GABAA receptor is, this agent represents by far the stronger positive allosteric
modulator than 2-AG, although the latter is more abundant in brain. The implications of
our findings for the analgesic effect of NA-glycine remain to be studied.
Abbreviations
GABA γ -aminobutyric acid
GABAA receptor γ -aminobutyric acid type A receptor
NA-glycine N-arachidonyl-glycine
2-AG 2-arachidonoyl glycerol
DEA docosatetraenylethanolamide
ACKNOWLEDGEMENTS
We thank Dr. V Niggli for carefully reading the manuscript and Dr. A Chicca for
determining stability of 2-AG in Xenopus oocytes.
ADDITIONAL INFORMATION AND DECLARATIONS
Funding
This work was supported by the Swiss National Science Foundation grants
31003A 132806/1 (ES) and 31003A 120672 (JG). The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the manuscript.
Grant Disclosures
The following grant information was disclosed by the authors:
Swiss National Science Foundation: 31003A 132806/1, 31003A 120672.
Competing Interests
The authors declare no competing interests.
Author Contributions
• Roland Baur performed the experiments, analyzed the data.
• Ju¨rg Gertsch contributed reagents/materials/analysis tools, wrote the paper.
• Erwin Sigel conceived and designed the experiments, analyzed the data, wrote the paper.
Baur et al. (2013), PeerJ, DOI 10.7717/peerj.149 13/15
Animal Ethics
The following information was supplied relating to ethical approvals (i.e., approving body
and any reference numbers):
Kantonaler Verterina¨rdienst, Kanton Bern
Approval No. BE98/12.
REFERENCES
Barbara G, Alloui A, Nargeot J, Lory P, Eschalier A, Bourinet E, Chemin J. 2009. T-type calcium
channel inhibition underlies the analgesic effects of the endogenous lipoamino acids. Journal of
Neuroscience 29:13106–13114 DOI 10.1523/JNEUROSCI.2919-09.2009.
Baumann SW, Baur R, Sigel E. 2001. Subunit arrangement of γ -aminobutyric acid type A
receptors. Journal of Biological Chemistry 276:36275–36280 DOI 10.1074/jbc.M105240200.
Baumann SW, Baur R, Sigel E. 2002. Forced subunit assembly in α1β2γ2 GABAA receptors.
Insight into the absolute arrangement. Journal of Biological Chemistry 277:46020–46025
DOI 10.1074/jbc.M207663200.
Baumann SW, Baur R, Sigel E. 2003. Individual properties of the two functional agonist sites in
GABAA receptors. Journal of Neuroscience 23:11158–11166.
Baur R, Kielar M, Richter L, Ernst M, Ecker GF, Sigel E. 2013. Molecular analysis of the site for
2-arachidonylglycerol (2-AG) on the β2 subunit of GABAA receptors. Journal of Neurochemistry
126:29–36 DOI 10.1111/jnc.12270.
Baur R, Minier F, Sigel E. 2006. A GABAA receptor of defined subunit composition and
positioning: concatenation of five subunits. FEBS Letters 580:1616–1620
DOI 10.1016/j.febslet.2006.02.002.
Belelli D, Lambert JJ. 2005. Neurosteroids: endogenous regulators of the GABAA receptor. Nature
Reviews in Neuroscience 6:565–575 DOI 10.1038/nrn1703.
Boileau AJ, Baur R, Sharkey LM, Sigel E, Czajkowski C. 2002. The relative amount of cRNA
coding for γ 2 subunits affects stimulation by benzodiazepines in GABAA receptors expressed
in Xenopus oocytes. Neuropharmacology 43:695–700 DOI 10.1016/S0028-3908(02)00036-9.
Bondarenko AI, Drachuk K, Panasiuk O, Sagach V, Deak AT, Malli R, Graier WF. 2013.
N-arachidonoyl glycine suppresses Na+/Ca2+ exchanger-mediated Ca2+ entry into endothelial
cells and activates BKCa channels independently of GPCRs. British Journal of Pharmacology
169:933–948 DOI 10.1111/bph.12180.
Chang Y, Wang R, Barot S, Weiss DS. 1996. Stoichiometry of a recombinant GABAA receptor.
Journal of Neuroscience 16:5415–5424.
Guasti L, Richardson D, Jhaveri M, Eldeeb K, Barrett D, Elphick MR, Alexander SPH,
Kendall D, Michael GJ, Chapman V. 2009. Minocycline treatment inhibits microglial
activation and alters spinal levels of endocannabinoids in a rat model of neuropathic pain.
Molecular Pain 5:35–45 DOI 10.1186/1744-8069-5-35.
Farrar SJ, Whiting PJ, Bonnert TP, McKernan RM. 1999. Stoichiometry of a ligand gated
ion channel determined by fluorescence energy transfer. Journal of Biological Chemistry
274:10100–10104 DOI 10.1074/jbc.274.15.10100.
Huang SM, Bisogno T, Petros TJ, Chang SY, Zavitsanos PA, Zipkin RE, Sivakumar R, Coop A,
Maeda DY, De Petrocellis L, Burstein S, Di Marzo V, Walker JM. 2001. Identification of a new
class of molecules, the arachidonyl amino acids, and characterization of one member that
inhibits pain. Journal of Biological Chemistry 276:42639–42644 DOI 10.1074/jbc.M107351200.
Baur et al. (2013), PeerJ, DOI 10.7717/peerj.149 14/15
Kohno M, Hasegawa H, Inoue A, Muraoka M, Miyazaki T, Oka K, Yasukawa M. 2006.
Identification of N-arachidonylglycine as the endogenous ligand for orphan G-protein-coupled
receptor GPR18. Biochemical and Biophysical Research Communications 347:827–832
DOI 10.1016/j.bbrc.2006.06.175.
Macdonald RL, Olsen RW. 1994. GABAA receptor channels. Annual Reviews in Neuroscience
17:569–602 DOI 10.1146/annurev.ne.17.030194.003033.
Minier F, Sigel E. 2004. Positioning of the α-subunit isoforms confers a functional signature to
γ -aminobutyric acid type A receptors. Proceedings of the National Academy of Sciences of the
United States of America 101:7769–7774 DOI 10.1073/pnas.0400220101.
Oh DY, Yoon JM, Moon MJ, Hwang JI, Choe H, Lee JY, Kim JI, Kim S, Rhim H, O’Dell DK,
Walker JM, Na HS, Lee MG, Kwon HB, Kim K, Seong JY. 2008. Identification of farnesyl
pyrophosphate and N-arachidonylglycine as endogenous ligands for GPR92. Journal of
Biological Chemistry 283:21054–21064 DOI 10.1074/jbc.M708908200.
Olsen RW, Sieghart W. 2008. International union of pharmacology. LXX. Subtypes of
γ -aminobutyric acidA receptors: classification on the basis of subunit composition, pharmacol-
ogy, and function. Update. Pharmacological Reviews 60:243–260 DOI 10.1124/pr.108.00505.
Raduner S, Bisson W, Abagyan R, Altmann KH, Gertsch J. 2007. Self-assembling
cannabinomimetics: supramolecular structures of N-alkyl amides. Journal of Natural Products
70:1010–1015 DOI 10.1021/np060598+.
Sheskin T, Hanus L, Slager J, Vogel Z, Mechoulam R. 1997. Structural requirements for binding
of anandamide-type compounds to the brain cannabinoid receptor. Journal of Medicinal
Chemistry 40:659–667 DOI 10.1021/jm960752x.
Sieghart W. 1995. Structure and pharmacology of gamma-aminobutyric acidA receptor subtypes.
Pharmacological Reviews 47:181–233.
Sieghart W, Sperk G. 2002. Subunit composition, distribution and function of GABAA receptor
subtypes. Current Topics Medicinal Chemistry 2:795–816 DOI 10.2174/1568026023393507.
Sigel E. 1987. Properties of single sodium channels translated by Xenopus oocytes after injection
with messenger ribonucleic acid. Journal of Physiology 386:73–90.
Sigel E, Minier F. 2005. The Xenopus oocyte: system for the study of functional expression
and modulation of proteins. Molecular Nutrition and Food Research 49:228–234
DOI 10.1002/mnfr.200400104.
Sigel E, Baur R, Trube G, Mohler H, Malherbe P. 1990. The effect of subunit combination of
rat brain GABAA receptors on channel function. Neuron 5:703–711 DOI 10.1016/0896-
6273(90)90224-4.
Sigel E, Baur R, Ra´cz I, Marazzi J, Smart TG, Zimmer A, Gertsch J. 2011. The major central
endocannabinoid directly acts at GABAA receptors. Proceedings of the National Academy of
Sciences of the United States of America 108:18150–18155 DOI 10.1073/pnas.1113444108.
Sigel E, Steinmann ME. 2012. Structure, function and modulation of GABAA receptors. Journal of
Biological Chemistry 287:40224–40231 DOI 10.1074/jbc.R112.386664.
Succar R, Mitchell VA, Vaughan CW. 2007. Actions of N-arachidonyl-glycine in a rat
inflammatory pain model. Molecular Pain 3:24–31 DOI 10.1186/1744-8069-3-24.
Tretter V, Ehya N, Fuchs K, Sieghart W. 1997. Stoichiometry and assembly of a recombinant
GABAA receptor subtype. Journal of Neuroscience 17:2728–2737.
Yevenes GE, Zeilhofer HU. 2011. Molecular sites for the positive allosteric modulation of glycine
receptors by endocannabinoids. PLoS ONE 6:e23886 DOI 10.1371/journal.pone.0023886.
Baur et al. (2013), PeerJ, DOI 10.7717/peerj.149 15/15
